| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Ann Thorac Surg 2006;82:220-226
© 2006 The Society of Thoracic Surgeons
a Division of Cardiothoracic Surgery, Departments of Surgery and Pathology and Area Laboratory Services, Walter Reed Army Medical Center, Washington, DC
b Division of Anatomic Pathology, Departments of Surgery and Pathology and Area Laboratory Services, Walter Reed Army Medical Center, Washington, DC
c United States Military Cancer Institute, Walter Reed Army Medical Center, Washington, DC
d Laboratory of Biomarkers and Carcinogenesis, CBCP-IRC, Department of Surgery, Uniformed Services University for Health Sciences, Bethesda, Maryland
Accepted for publication February 13, 2006.
* Address correspondence to Major Mulligan, Cardiothoracic Surgery, Rm 4655, Bldg 2, Walter Reed Army Medical Center, 6900 Georgia Ave NW, Washington, DC 20307-5001 (Email: charles.mulligan{at}na.amedd.army.mil).
Presented at the Poster Session of the Fifty-second Annual Meeting of the Southern Thoracic Surgical Association, Orlando, FL, Nov 10–12, 2005.
BACKGROUND: The purpose of this study is to determine a more refined T definition for lung cancer staging on the basis of clinical outcomes.
METHODS: The Walter Reed Army Medical Center Tumor Registry and the Thoracic Surgery Tumor Clinic files were queried for lung cancers diagnosed from 1990 to 2000. Cox regression analysis and Kaplan–Meier survival curves for tumor size were used to analyze the impact of size on survival and relative risk, and then used to redefine T. Using the new T definition, the cohort was restaged, and the two staging system survivals were compared using Cox regression analysis.
RESULTS: Tumor size was documented in 439 males and 226 females. Forty-two tumors were 1.0 cm or less, 133 were between 1.01 and 2.0 cm, 133 were between 2.01 and 3.0 cm, 91 were between 3.01 and 4.0, 96 were between 4.01 and 5.0, and 166 were greater than 5.0 cm. A survival advantage was noted for smaller lesions, with 5-year survivals of 48.6%, 45.9%, 26.6%, 27.0%, 14.4%, and 11.6%, respectively. Cox regression analysis revealed increased risk at 2.0 cm (hazards ratio, 2.014; 95% confidence interval, 1.24 to 3.26), 4.0 cm (hazards ratio, 2.51; 95% confidence interval, 1.53 to 4.09), and 5.0 cm (hazards ratio, 3.14; 95% confidence interval, 1.96 to 5.02). After redefining T, the new staging system showed a better 5-year survival in each stage.
CONCLUSIONS: Lung cancer tumor size criteria should be changed to include T1 tumors 2.0 cm and less; T2 tumors between 2.0 and 4.0 cm or pleural invasion of T1 tumor; T3 tumors greater than 4.0 cm or pleural invasion of T2 tumors.
This article has been cited by other articles:
|
|
 |
|
  A. Yilmaz, S. S. Duyar, E. Cakir, E. Aydin, F. Demirag, J. Karakaya, U. Yazici, and Y. Erdogan Clinical impact of visceral pleural, lymphovascular and perineural invasion in completely resected non-small cell lung cancer Eur J Cardiothorac Surg, September 1, 2011; 40(3): 664 - 670. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Ruffini, P. L. Filosso, M. C. Bruna, F. Coni, R. C. Cristofori, C. Mossetti, P. Solidoro, and A. Oliaro Recommended changes for T and N descriptors proposed by the International Association for the Study of Lung Cancer -- Lung Cancer Staging Project: a validation study from a single-centre experience Eur J Cardiothorac Surg, December 1, 2009; 36(6): 1037 - 1044. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S.-H. I. Ou, J. A. Zell, A. Ziogas, and H. Anton-Culver Prognostic Significance of the Non-Size-Based AJCC T2 Descriptors: Visceral Pleura Invasion, Hilar Atelectasis, or Obstructive Pneumonitis in Stage IB Non-small Cell Lung Cancer Is Dependent on Tumor Size Chest, March 1, 2008; 133(3): 662 - 669. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |
